Virtual screening reveals aprepitant to be a potent inhibitor of neutral sphingomyelinase 2: implications in blockade of exosome release in cancer therapy

[1]  J. Neuzil,et al.  Mitochondria on the move: Horizontal mitochondrial transfer in disease and health , 2023, The Journal of cell biology.

[2]  M. Farhadi,et al.  Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity , 2023, Journal of Cancer Research and Clinical Oncology.

[3]  Anjali Sharma,et al.  Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice , 2022, Pharmaceutics.

[4]  P. Ordóñez-Morán,et al.  Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness , 2022, Cancers.

[5]  Ashwag S Alanazi,et al.  Network Pharmacology- and Molecular Docking-Based Identification of Potential Phytocompounds from Argyreia capitiformis in the Treatment of Inflammation , 2022, Evidence-based complementary and alternative medicine : eCAM.

[6]  A. Afshari,et al.  Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-κB Axis in Cancer Stem-Like Esophageal Squamous Cell Carcinoma Spheres , 2021, BioMed research international.

[7]  A. Lyakhovich,et al.  Movement of Mitochondria with Mutant DNA through Extracellular Vesicles Helps Cancer Cells Acquire Chemoresistance , 2021, ChemMedChem.

[8]  Zhijie Xu,et al.  Exosomes: A New Pathway for Cancer Drug Resistance , 2021, Frontiers in Oncology.

[9]  M. Mohammadnia-Afrouzi,et al.  Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin , 2021, Frontiers in Immunology.

[10]  M. Moloudizargari,et al.  Exosomal microRNA panels as biomarkers for hematological malignancies. , 2021, Current problems in cancer.

[11]  M. Kaulich,et al.  Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance , 2021, Cells.

[12]  M. Shabbir,et al.  Molecular Docking Using Chimera and Autodock Vina Software for Nonbioinformaticians , 2020, JMIR Bioinformatics and Biotechnology.

[13]  Lin Chen,et al.  Exosomes: roles and therapeutic potential in osteoarthritis , 2020, Bone Research.

[14]  K. Vadivel,et al.  Dual Neutral Sphingomyelinase-2/Acetylcholinesterase Inhibitors for the treatment of Alzheimer's disease. , 2020, ACS chemical biology.

[15]  Sooho Yeo,et al.  Design and Characterization of Phosphatidylcholine-Based Solid Dispersions of Aprepitant for Enhanced Solubility and Dissolution , 2020, Pharmaceutics.

[16]  L. Roshangar,et al.  Tumor microenvironment complexity and therapeutic implications at a glance , 2020, Cell Communication and Signaling.

[17]  B. Slusher,et al.  A novel and potent brain penetrant inhibitor of extracellular vesicle release , 2019, British journal of pharmacology.

[18]  E. Mortaz,et al.  Inhibiting exosomal MIC-A and MIC-B shedding of cancer cells to overcome immune escape: new insight of approved drugs , 2019, DARU Journal of Pharmaceutical Sciences.

[19]  M. Abdollahi,et al.  The emerging role of exosomes in multiple myeloma. , 2019, Blood reviews.

[20]  Xiaozhuo Chen,et al.  Drug resistance and combating drug resistance in cancer , 2019, Cancer drug resistance.

[21]  S. Skvortsov,et al.  Therapy resistance mediated by exosomes , 2019, Molecular Cancer.

[22]  K. Kang,et al.  Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A , 2019, Nature Communications.

[23]  M. Ferrer,et al.  DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation , 2018, Scientific Reports.

[24]  Mohammad Abdollahi,et al.  Modifying exosome release in cancer therapy: How can it help? , 2018, Pharmacological research.

[25]  M. Ferrer,et al.  High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer , 2018, Scientific Reports.

[26]  Wolfram-Hubertus Zimmermann,et al.  Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin , 2018, Cancer biology & therapy.

[27]  J. Inal,et al.  Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy , 2017, International journal of molecular sciences.

[28]  Wanyeon Kim,et al.  The role of tumor microenvironment in therapeutic resistance , 2016, Oncotarget.

[29]  R. Hill,et al.  CANCER-ASSOCIATED FIBROBLAST EXOSOMES REGULATE SURVIVAL AND PROLIFERATION OF PANCREATIC CANCER CELLS , 2016, Oncogene.

[30]  V. Imbert,et al.  Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. , 2016, Blood.

[31]  J. McArthur,et al.  Cambinol, a Novel Inhibitor of Neutral Sphingomyelinase 2 Shows Neuroprotective Properties , 2015, PloS one.

[32]  V. Almendro,et al.  The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. , 2014, International journal of oncology.

[33]  D. V. von Schweinitz,et al.  Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. , 2014, Journal of hepatology.

[34]  Stephen T. C. Wong,et al.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. , 2014, Drug discovery today.

[35]  N. Tamimi,et al.  Drug Development: From Concept to Marketing! , 2009, Nephron Clinical Practice.

[36]  Petra Schwille,et al.  Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes , 2008, Science.

[37]  Karen C. Thompson,et al.  Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant , 2007, International journal of nanomedicine.